ENDRA Life Sciences Inc.
NDRA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 0.06 | 0.01 | -0.00 |
| FCF Yield | -28.42% | -44.25% | -57.32% | -45.10% |
| EV / EBITDA | -2.46 | -1.06 | -0.82 | -0.17 |
| Quality | ||||
| ROIC | -96.43% | -55.15% | -53.80% | -108.94% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.73 | 0.91 | 1.25 | 0.37 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -4.52% | 15.01% | 13.54% | 8.54% |
| Safety | ||||
| Net Debt / EBITDA | 0.17 | 1.05 | 1.49 | 0.64 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -576.92 | -773.99 | -441.47 | -523.51 |